Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
LFVN — LifeVantage Corporation
NASDAQ
FULL STOCK PAGE →

LifeVantage Corporation (LFVN) Q1 2026 Earnings Call Summary

NOV 4, 2025 2 MIN READ
REVENUE
$47.6M -13.7%
NET MARGIN
4.5% +1.0 PTS
EPS
$0.17 +6.3%
FREE CASH FLOW
-$2.7M -428.6%

1Key Financial Results and Metrics

Net Revenue: $47.6 million, a slight increase of 0.7% from $47.2 million in Q1 2025.

Adjusted EBITDA: $3.9 million, down from $4.4 million in the prior year, reflecting lower contribution margins.

Adjusted Non-GAAP Net Income: $2.3 million ($0.18 per diluted share), compared to $1.9 million ($0.15 per share) in Q1 2025.

Gross Margin: 79.5%, a decrease of 40 basis points year-over-year due to increased shipping and warehouse expenses.

SG&A Expenses: $14.6 million, slightly down from $14.7 million in the prior year.

Cash Position: $13.1 million with no debt; $5 million revolving credit available.

Share Repurchase: 44,000 shares repurchased at an average price of $13 per share.

2Strategic Updates and Business Highlights

Acquisition of LoveBiome: Closed on October 1, 2025, enhancing LifeVantage's position in the growing gut health market, projected to reach $32.4 billion by 2035.

Product Integration: The integration of LoveBiome's systems and consultant community is complete, with cross-selling training underway.

E-commerce Partnership: Progress made with Shopify to modernize the technology infrastructure and improve consumer engagement.

Momentum Academy Event: Held in Dallas, showcasing the integration of consultant communities and new product launches, with nearly 2,000 attendees.

3Forward Guidance and Outlook

Full-Year Revenue Guidance: Expected to be between $225 million and $240 million, including contributions from LoveBiome.

Profitability Outlook: Adjusted EBITDA expected in the range of $23 million to $26 million, with adjusted EPS projected between $1.00 and $1.15.

Seasonal Expectations: Anticipation of higher revenues in the second half of fiscal 2026 due to the seasonal nature of the MindBody product line and the impact of the LoveBiome acquisition.

4Bad News, Challenges, or Points of Concern

Declining Metrics: Adjusted EBITDA and gross margins have decreased compared to the previous year, raising concerns about cost management.

Consultant Activity: A noted decrease in active consultants during the summer months, which is a historical trend but may indicate challenges in engagement.

Competitive Pressures: The wellness market is increasingly competitive, necessitating continuous innovation and effective marketing strategies.

5Notable Q&A Insights

Impact of LoveBiome: No revenue contribution from LoveBiome in Q1 as the acquisition closed at the start of October. Management noted a potential pause in activity from LifeVantage consultants in anticipation of the acquisition.

Seasonality: Q1 is typically a low quarter, and management acknowledged that comparisons to the previous year were challenging due to a strong prior launch.

Future Potential: Management expressed optimism about the second half of the fiscal year, anticipating significant benefits from the LoveBiome integration and the seasonal uptick in MindBody product sales. Overall, while LifeVantage reported slight revenue growth and strategic advancements through acquisitions and partnerships, challenges such as declining EBITDA and seasonal consultant activity remain points of concern. The company is optimistic about future growth driven by the integration of LoveBiome and upcoming product launches.

SOURCE: Q1 2026 EARNINGS CALL TRANSCRIPT